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Which placebo to cure depression? A
thought-provoking network meta-analysis
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and Bruno Falissard1,8,9
Abstract
Background: Antidepressants are often considered to be mere placebos despite the fact that meta-analyses are
able to rank them. It follows that it should also be possible to rank different placebos, which are all made of
sucrose. To explore this issue, which is rather more epistemological than clinical, we designed an unusual
meta-analysis to investigate whether the effects of placebo in one situation are different from the effects of placebo
in another situation.
Methods: Published and unpublished studies were searched for by three reviewers on Medline, the Cochrane
Library, Embase, clinicaltrials.gov, Current Controlled Trial, in bibliographies, and by mailing key organizations. The
following studies in first-line treatment for major depressive disorder were considered to construct an “evidence
network”: 1) randomized controlled trials (RCTs) versus placebo on fluoxetine, venlafaxine and 2) fluoxetine versus
venlafaxine head-to-head RCTs.
Two network meta-analyses were run to indirectly compare response and remission rates among three different
placebos: 1) fluoxetine placebo, 2) venlafaxine placebo, and 3) venlafaxine/fluoxetine placebo (that is, placebo
compared to both venlafaxine and fluoxetine). Publication biases were assessed using funnel plots and statistically
tested.
Results: The three placebos were not significantly different in terms of response or remission. The antidepressant
agents were significantly more efficacious than the placebos, and venlafaxine was more efficacious than fluoxetine.
The funnel plots, however, showed a major publication bias.
Conclusion: The presence of significant levels of publication bias indicates that we cannot even be certain of the
conclusion that sucrose equals sucrose in trials of major depressive disorder. This result should remind clinicians to
step back to take a more objective view when interpreting a scientific result. It is of crucial importance for their
practice, far more so than ranking antidepressant efficacy.
Keywords: Antidepressants, Placebo, Major depressive disorder, Meta-analysis, Publication bias
Background
The history of medicine is closely linked to the history
of placebos. Pre-scientific medicine was based on many
bizarre and ineffective medical interventions and on the
belief that such treatments were effective [1]. Placebo
was used for the first time as a control in 1784 to
debunk the healing claims of mesmerism [2], and it
became a standard control in experimental procedures
in the second half of the 20th century. Randomized con-
trolled trials (RCTs) against placebo have enabled major
progress in modern medicine. Nevertheless, these stu-
dies have limitations in terms of external validity and
even internal validity, and antidepressant literature on
major depressive disorder is a striking example of these
limitations: some practitioners and researchers [3] con-
sider that most of the antidepressant efficacy reflects
simply the placebo effect, especially for depression in pa-
tients with mild or moderate symptoms [4,5]. However,
many patients are satisfied with these treatments, many
* Correspondence: floriannaudet@gmail.com
1INSERM U669, Maison de Solenn, 97 Boulevard de Port Royal, 75679 Paris
Cedex 14, France
2Université de Rennes 1, EA-4712 Behavior and Basal Ganglia Unit, Rennes,
France
Full list of author information is available at the end of the article
© 2013 Naudet et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Naudet et al. BMC Medicine 2013, 11:230
http://www.biomedcentral.com/1741-7015/11/230
clinicians trust them and use them, and a large part of
discussions during medical staff meetings is devoted to
the choice of the right sort of antidepressant drug [6].
Recently, Cipriani et al. in a multiple-treatment meta-
analysis, ranked 12 new-generation antidepressants [7]
to address this question.
This state-of-the-art raises a fundamental question: if
much of the effect of antidepressants is attributable to
the placebo effect and if it is possible to rank antidepres-
sants, then it should also be possible to rank different
placebos, which are all made of sucrose. In a more glo-
bal perspective, it questions whether or not we can be
certain about anything in psychiatry (or, indeed, in medi-
cine), and, in particular, whether the evidence that we
usually rely on provides us with a reasonable degree of
certainty about the nature and effectiveness of our prac-
tices. We set about investigating this question, which is
rather more epistemological than clinical, by investiga-
ting whether the effects of placebo in one situation are
different from the effects of placebo in another situation.
We thus designed an unusual meta-analysis on aggre-
gated data which allows us to examine the apparently
incontrovertible fact that sucrose equals sucrose by com-
paring the placebos of two famous antidepressant block-
busters: 1) fluoxetine, one of the first selective serotonin
reuptake inhibitors available on the market, which has
become a reference drug, and 2) venlafaxine, a serotonin-
norepinephrine reuptake inhibitor.
Methods
Eligibility criteria
Types of participants
We reviewed studies involving adults (age 18 and over)
with a diagnosis of major depressive episode (DSM IV,
DSM IV-R, DSM III, DSM III-R, ICD 10, Feighner cri-
teria, Research Diagnostic Criteria). Studies involving pa-
tients with other psychiatric or medical comorbidity were
considered only when it was not an explicit inclusion cri-
terion for the study. Studies involving patients with a diag-
nosis of anxious depression were also considered.
Studies involving more than 20% subjects with bipolar
disorder were excluded, as were studies exclusively in-
volving patients with seasonal affective disorder, post-
partum depression, postmenopausal depression, atypical
depression, dysthymia and studies involving elderly
patients.
Types of intervention(s)
Our primary aim was to compare placebo arms. We
focused our attention on three different placebos: 1)
fluoxetine placebo (FLUp, where placebo was com-
pared to fluoxetine), 2) venlafaxine placebo (VENLAFp,
where placebo was compared to venlafaxine), and 3)
venlafaxine/fluoxetine placebo (FLU/VENLAFp, where
placebo was compared to both venlafaxine and fluoxe-
tine), which were obviously compared with the corre-
sponding antidepressants in oral mono-therapy in major
depressive disorder first line acute treatment.
Types of outcomes
Response was chosen as the primary outcome. Remis-
sion was chosen as a secondary outcome. These out-
comes are the most consistently reported estimates of
acute-treatment efficacy. Response was defined as the
proportion of patients who had a reduction of at least
50% from the baseline score on the Hamilton Depression
Rating Scale (HDRS) [8] or the Montgomery-Åsberg De-
pression Rating Scale (MADRS) [9]. Remission was de-
fined as the proportion of patients who had a HDRS
score ≤7 or a MADRS score ≤12.
When trials reported results from both rating scales,
we extracted data from the scale considered in the study
as the primary outcome.
Types of studies
In this review were included 1) randomized controlled
trials of fluoxetine or venlafaxine against placebo and 2)
head-to-head trials of fluoxetine versus venlafaxine with
or without placebo control. All studies were conducted
from January 1989 to July 2009. Only study reports in
English, French and Spanish language were considered.
Search strategy
We used the search strategy from an earlier paper [10]
on venlafaxine and fluoxetine to conduct this meta-
analysis on aggregated data.
Eligible studies were identified from PubMed/Medline,
the Cochrane library and Embase, including congress ab-
stracts. A three-step search was used for each compo-
nent of this review. In a first step, an initial search on
Medline was carried out in order to refresh optimal
search terms and include possible changes in the da-
tabases. The search terms used were double-checked
before starting the main search. In a second step, all key-
words identified were used to search all the above-
mentioned databases. A third search was undertaken by
searching the reference lists of articles identified. Initial
keywords used were: “Depressive Disorder NOT Depres-
sion, Postpartum NOT Seasonal Affective Disorder”;
“Antidepressive Agents”; “Fluoxetine”; “Venlafaxine”. In
addition, manual searches of articles were performed in
previous meta-analyses.
Unpublished studies were searched for by commu-
nication with key organizations such as the Food and
Drug Administration (FDA) and the European Medi-
cines Agency (EMEA), and key researchers in the area.
A search on clinicaltrials.gov and Current Controlled
Trial was performed.
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Authors of abstracts or meta-analysis were contacted
for further information and were asked for references of
the studies when needed. If no response was obtained to a
first solicitation, they were then contacted a second time.
Study selection
Eligibility assessment was performed independently in a
blinded standardized manner by two reviewers (NF and
MAS). Disagreements were resolved by consensus or in
consultation with a third reviewer (FB).
A comparison across the studies, checking author
names, treatment comparisons, sample sizes and out-
comes was performed to avoid duplicates and compila-
tions of data from several reports of the same study.
Assessment of methodological quality
Each paper was then assessed for methodological quality
prior to inclusion in the review using an appropriate
standardized critical appraisal instrument from the Joanna
Briggs Institute [11].
Data collection
A data extraction sheet based on the Cochrane Hand-
book for Systematic Reviews of Interventions’ guidelines
(Version 5.0.2, updated September 2009) [12] was used.
One review author (NF) extracted these data from the
studies included.
Data analysis
The dichotomous outcomes used here are considered
as robust outcome measures of treatment efficacy [7].
When these outcomes were not reported, the studies
were excluded, and no imputation method was used. Re-
sponder and remitter data were extracted as the original
study investigators analyzed the data, mainly using the
LOCF (Last Observation Carried Forward) method.
Head-to-head direct evidence
We used visual inspection of the forest plots and the Q
statistic [13] to investigate the possibility of statistical
heterogeneity. In the absence of heterogeneity we per-
formed pair-wise meta-analyses by synthesizing studies
that compared the same interventions with a fixed-
effects model (Mantel-Haenszel); in case of possible he-
terogeneity, we performed pair-wise meta-analysis with a
random effect model (DerSimonian and Laird).
Network meta-analyses to enable indirect comparisons
In a second step, to compare indirectly the different
placebos, and following recommendations by Glenny
et al. [14], two network meta-analyses [15,16] were run.
The dependent variables were 1) response and 2) remis-
sion; the treatment was considered as the explanatory
variables (fluoxetine, venlafaxine, FLUp, VENLAFp and
FLU/VENLAFp). Both fixed effect and random effect
approaches were performed for each network meta-
analysis; final models were selected by comparing
a model fit criterion (Akaïke’s Information Criterion
(AIC)). Results of these meta-analyses are the odds ratio
(OR) between treatments with their 95% confidence
interval and the statistical significance level of the
comparison.
Risk of bias across studies
Publication bias was investigated graphically using fun-
nel plots for each fixed effect meta-analysis. Funnel plot
asymmetry was tested using the rank correlation test
when there were at least 10 studies [17].
Analyses were performed using R [18] with libraries
meta [19], rmeta [20] and lme4 [21] (lmer function,
family = binomial). Results are presented according to
PRISMA (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) statements [22].
Results
Study selection
The search of Medline, Cochrane and Embase databases
provided a total of 11,051 citations. An additional 66
studies were identified by manual search. After adjusting
for duplicates, 4,615 remained. Of these, 4,063 studies
were discarded because, after review of the abstracts, it
appeared that these papers did not meet the criteria. A
total of 114 studies were excluded because of the
language (among which 97 were in Chinese). Of 33 un-
published relevant studies identified, only 3 were made
available by pharmaceutical firms. Thirty-one studies
were included in the quantitative review. A flow-chart
detailing the study selection process is given in Figure 1.
Study characteristics and risk of bias within studies
A summary of the methodologies of these 31 studies is
given in Table 1. The quality of the different studies is
presented as a table in a web appendix (Additional file 1:
Table S1). The “response” analysis involved 29 RCTs in-
cluding 7,459 participants and the “remission” analysis
involved 20 RCTs including 5,096 participants.
Results from individual studies and synthesis of results
Head-to-head direct evidence
Using the Q statistic, no significant heterogeneity was
detected for fluoxetine versus placebo, venlafaxine ver-
sus placebo or for fluoxetine versus venlafaxine in the
response and remission meta-analyses. Nevertheless, as
visual inspection of the forest plot suggested that hetero-
geneity could not be totally excluded, and as heterogen-
eity tests are often under-powered [23], we ran pair-wise
fixed effects and random effects models which found the
same results.
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Results of the head-to-head direct meta-analysis using
a fixed-effects model are presented in Figure 2 and in
the web-appendix (Additional file 1: Table S2) and re-
sults of random-effects model are presented in the web
appendix (Additional file 1: Table S2 and Additional file 1:
Figure S1): regarding treatment response, placebo ap-
peared less effective than both fluoxetine and venlafaxine.
Fluoxetine appeared less effective than venlafaxine.
Network meta-analyses to enable indirect comparisons
Figure 3 shows all the available evidence for the meta-
analysis concerning the response. Concerning the two
network meta-analyses (response and remission), AIC
(presented in the e-appendix, Additional file 1: Table S3)
was in favor of the selection of the fixed effect network
meta-analysis (which fits the data better).
Table 2 summarizes the results of these two fixed-
effect network meta-analyses concerning response and
remission. The three placebos were not significantly dif-
ferent in terms of response (P = 0.33 for FLU/VENLAFp
versus VENLAFp, P = 0.50 for FLU/VENLAFp versus
FLUp and P = 0.85 for VENLAFp versus FLUp) or re-
mission (P = 0.88 for FLU/VENLAFp versus VENLAFp,
P = 0.66 for FLU/VENLAFp versus FLUp and P = 0.76 for
VENLAFp versus FLUp). Antidepressant agents were sig-
nificantly more efficacious than placebos and venlafaxine
Figure 1 Flow diagram.
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was more efficacious than fluoxetine. Results of the ran-
dom effect meta-analysis were coherent and are presented
in the web-appendix (Additional file 1: Table S4).
Risk of bias across studies
Six funnel plots were drawn (three for response and
three for remission for each head-to-head direct meta-
analysis, Figure 4). The funnel plots of the meta-analysis
comparing venlafaxine to fluoxetine showed some asym-
metry (P <0.03 for response and P <0.01 for remission).
The asymmetry was less striking for funnel plots of
meta-analyses for both active treatments versus placebo.
Discussion
Summary of evidence
The three placebos considered were not significantly dif-
ferent in terms of response or remission. Antidepressant
agents were significantly more efficacious than placebos,
and venlafaxine was more efficacious than fluoxetine.
This was coherent with previous meta-analyses [7,24].
Thus, venlafaxine placebo appears as a “me-too” placebo
without greater benefit in relation to fluoxetine placebo
and/or fluoxetine and venlafaxine placebo.
Since, obviously, no direct evidence of well-po-
wered, randomized, direct-comparisons exist, indirect
comparisons were the only option for comparing the three
different placebos. Such indirect evidence is not totally the
same as direct evidence and in some cases it has been
shown that indirect comparisons led to conflicting results
as compared with direct evidence. Such a paradox has
been recently shown concerning antidepressants in a re-
cent paper comparing citalopram with its “me-too” escita-
lopram which found an inconsistency between direct
evidence (showing a superiority of escitalopram) and in-
direct evidence (which did not find any significant diffe-
rence) [25]. Additionally, Song et al. have suggested that
in some cases indirect evidence is less biased than direct
evidence [26]. Moreover, the validity of indirect compari-
son is dependent on the distribution of relative treatment
effect modifiers across different comparisons [27]. In our
study, initial severity (HDRS score ≥25) could be an im-
portant effect modifier [4,5] but despite slight variations,
its distribution seemed well-balanced across the different
direct comparisons (that is, there was no systematic dif-
ference in its distribution between the different direct
comparisons).
Nevertheless, results of our indirect comparisons were
consistent with the implicit conception that if the three
placebos (all made of the same sucrose) were compared
in a double blind randomized trial, no difference would
Table 1 Summary of study methodology
V vs F vs P (n = 4) V vs F (n = 8) V vs P (n = 10) F vs P (n = 9) Total (n = 31)
Year (1999, 2003,
2004, 2009)
(1994, 1997, 1998,
2000, 2007)
(1993, 1996, 1997,
1998, 2004)
(1991, 1998, 2002,
2004, 2005)
(1991, 1997, 1999,
2003, 2009)
Anxious depression (No) 3 (75%) 7 (88%) 10 (100%) 8 (89%) 28 (90%)
Study duration (weeks) (6, 6, 8, 12) (6, 8, 9, 12, 12) (4, 6, 8, 11, 13) (4, 6, 8, 12, 13) (4, 6, 8, 12, 13)
Number of follow-up visits (6, 7, 8, 8) (6, 6, 7, 8, 9) (NA = 1) (5, 6, 7, 8, 8) (3, 8, 9, 9, 9) (NA = 1) (3, 6, 7, 8, 9) (NA = 2)
Industry sponsorship (yes) 4 (100%) 8 (100%) 10 (100%) 8 (100%) (NA = 1) 30 (100%) (NA = 1)
Exclusion of placebo responders (yes) 4 (100%) 5 (63%) 10 (100%) 6 (75%) (NA = 1) 25 (83%) (NA = 1)
Patient type (NA = 1) (NA = 1) (NA = 2)
Inpatients 1 (25%) 2 (25%) 1 (11%) 1 (12.5%) 5 (17%)
Outpatients 3 (75%) 5 (63%) 7 (78%) 6 (75%) 21 (73%)
Outpatients in primary care 0 (0%) 1 (12%) 1 (11%) 1 (12.5%) 3 (10%)
Scale used
HDRS 4 (100%) 5 (63%) 4 (40%) 8 (89%) 23 (74%)
MADRS 0 (0%) 3 (37%) 6 (60%) 1 (11%) 8 (26%)
Type of analysis
ITT with LOCF 4 (100%) 8 (100%) 10 (100%) 8 (89%) 30 (97%)
Mixed model 0 (0%) 0 (0%) 0 (0%) 1 (11%) 1 (3%)
Initial severity (HDRS score ≥25) 3 (75%) 5 (63%) 6 (60%) 3 (37.5%) (NA = 1) 17 (57%) (NA = 1)
n, number of studies. Results are presented in (minimum, first quartile, median, third quartile, maximum) for quantitative data except for V vs F vs P where all the
data are given. Qualitative data are presented as a number (percentage). NA represents the number of studies where data were unavailable.
V vs F vs P: studies comparing venlafaxine to fluoxetine to placebo.
V vs F: studies comparing venlafaxine to fluoxetine.
V vs P: studies comparing venlafaxine to placebo.
F vs P: studies comparing fluoxetine to placebo.
HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale.
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be observed. These results are good news indeed: 1) for
the supporters of placebo because they conclude that the
choice of the placebo is not really important, 2) for the
supporters of antidepressants because antidepressants
prove superior to placebos, and 3) for supporters of
rationality because a validated method has not led to
invalid conclusions, that is, we have managed to con-
clude that “sucrose equals sucrose” in the treatment of
major depressive disorder, which is wholly reassuring.
Yet significant limitations question these findings.
Limitations
The quality of a meta-analysis is linked to the quality of
the individual studies included [28]. In this respect, the
National Institute for Health and Clinical Excellence
(NICE) guideline on the treatment and management of
depression in adults [29] advises caution in the applica-
tion of results from RCTs and meta-analyses in routine
practice. In particular, our model is based on the postu-
late that all placebo responders should be antidepressant
responders (additive model). This key assumption has
never been proved to be true. Indeed, antidepressant
response and placebo response could be independent
or at least substantially overlapping phenomena (non-
additive model), with four different types of patients: 1)
placebo-only responders, 2) treatment-only responders,
3) placebo and treatment responders, and 4) never re-
sponders [30]. Moreover, the classic logic of the random-
ized controlled trial casts the placebo effect as a negative
foil for measuring therapeutic efficacy and a large
amount of important information concerning placebo is
not reported in these studies, such as the appearance of
the medication (size, shape and color of the pills) [31].
As well, the indirect comparison may have had low
statistical power. Even if no trend toward statistical sig-
nificance was observed within the indirect comparisons
of placebos, insignificant P-values never tell much about
equivalence [32].
Above all, a publication bias and a selective outcome
reporting bias might account for some of the effects we
observed. The funnel plot for comparison between ven-
lafaxine and fluoxetine shows some asymmetry in favor
of venlafaxine. As “true heterogeneity” could not explain
this result, and since studies on antidepressants generate
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Figure 2 Forest plots. Forest plots present head-to-head meta-analyses using fixed-effects model for response and remission comparing
1) placebo vs fluoxetine, 2) placebo vs venlafaxine and 3) fluoxetine vs venlafaxine.
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substantial conflicts of interest (these drugs generate
vast sales revenues), the result is very much open to sus-
picion of reporting bias [17]. Concerning comparisons
between active antidepressants and placebo, no evidence
was found for a publication bias, but as statistical tests
for asymmetry typically have low power [17], this bias
cannot be excluded. The bias is well known [33] and, for
example, it has led to considering reboxetine as a serious
antidepressant agent, whereas it is probably ineffective
and potentially harmful [34]. It has been recently de-
monstrated that the selective reporting of studies in net-
work meta-analysis of antidepressants biases estimates
of relative treatment efficacy [35].
Various barriers were encountered in our meta-analytic
quest for exhaustiveness: many trials were carried out in
China and published in Chinese journals. Nevertheless,
the quality of many of these studies could be expected to
be poor [36], and excluding these trials, although it means
a loss of randomized evidence, thus avoids other major
biases.
Moreover - and this is probably the main problem - anti-
depressant research is completely controlled by the pharma-
ceutical industry [37]: 1) the firms that promoted some of
the trials we identified refused to communicate results from
these studies; 2) in this meta-analysis all the studies were
sponsored by the pharmaceutical industry. Such studies have
been shown to be more likely to demonstrate positive effects
for the sponsor’s drug than independent studies [38].
Perspectives
Thus, in view of these limitations, a reasonable measure
of skepticism should discourage hasty conclusions. They
illustrate the fact that every scientific result is uncertain
and that it is difficult to be sure of an individual study
conclusion, even if it explored something as patently
obvious as “sucrose = sucrose”, however rigorous the
method. Nevertheless, although published research find-
ings can be erroneous [39], Science often generates rep-
resentations that leave no room for skepticism. This is
probably the most insidious pitfall in Evidence-Based
Medicine; it does not concern the findings of Science, it
concerns academics’ understanding of Science (the
knowledge-producing activity). The present-day context
of medicalization of modern society [40] implicitly dic-
tates that scientific results should have the status of
Truth. Concerning major depressive disorder, although
it is likely to be untrue, clinicians and a great number of
patients [41] strongly believe that antidepressant drugs
target a specific biological state that produces depression
[42] and the pleasing serotonin hypothesis is often taken
as gospel [43].
As for the study by Cipriani et al., it was disputed
with similar arguments to those set out in the present
study [37,44-47] and its results were not replicated by
Gartlehner et al. [48]. Moreover, whereas in our study
insignificant P-values do not tell much about equivalence,
in over-powered studies, like Cipriani’s study, statistically
significant differences never tell much about clinically
significant differences [32]. It is nevertheless mentioned
in the NICE guideline [29], with some kind of double
Venlafaxine
(n = 3,498)
Venlafaxine/Fluoxetine placebo
(n= 413)
Fluoxetine
(n = 2,056)
Venlafaxine placebo
(n= 1,010)
Fluoxetine placebo
(n= 482)
Figure 3 Summary of the evidence used in the network
meta-analysis for response rate. The thickness of the lines is
proportional to the number of trials comparing each pair of
treatments, and the size of each node is proportional to the number
of randomized participants (n = sample size). The network of eligible
comparisons for remission analysis was similar (with fewer patients
and comparisons).
Table 2 Results of the network meta-analyses
FLUp 1.03 [0.75 to 1.41] 0.88 [0.63 to 1.25] 0.58 [0.46 to 0.74] 0.46 [0.35 to 0.60]
0.94 [0.61 to 1.43] VENLAFp 0.86 [0.64 to 1.16] 0.57 [0.46 to 0.70] 0.45 [0.37 to 0.52]
0.91 [0.59 to 1.39] 0.97 [0.66 to 1.42] FLU/VENLAFp 0.66 [0.51 to 0.84] 0.51 [0.40 to 0.66]
0.51 [0.37 to 0.71] 0.55 [0.41 to 0.73] 0.57 [0.42 to 0.76] FLU 0.79 [0.68 to 0.91]
0.44 [0.31 to 0.63] 0.47 [0.37 to 0.61] 0.49 [0.36 to 0.65] 0.86 [0.74 to 1.00] VENLAF
Results of the network meta-analyses are the Odds ratio (OR) between treatment in the column and treatment in the row with their 95% confidence interval. For
response (in bold), OR higher than one favor the treatment indicated in the row. For remission (not in bold), OR higher than one favor the treatment indicated in
the column. To obtain OR for comparisons in the opposite direction, reciprocals should be taken. Significant results are underscored.
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bind: qualitatively no recommendations for ranking
antidepressants are made, but quantitatively special
emphasis is placed on the study (Cipriani’s name is cited
23 times versus 3 times for Gartlehner, tables present
the results, and so on). What is more, in day-to-day
practice, clinicians generally consider that Cipriani’s study
is solid evidence for choosing antidepressants when
treating a patient with newly diagnosed depression [49].
Uncertainty is sometimes acknowledged theoretically,
but not in clinical practice.
This epistemological position translates into the well-
known anthropological observation that the hopes and
expectations of the physician are just as crucial as those
of the patient in the healing process [50]. This suggests
that while the opposite may not be true, the best place-
bos to treat Major Depressive disorder could be antide-
pressants because they are believed to be effective,
which is probably an important determinant in the pla-
cebo effect [51].
Nonetheless, we cannot simply assume that, because
patients appear to improve on placebos in the short term,
as we observe in randomized controlled trials, placebos
have demonstrated the required cost-benefit balance.
When one uses a treatment that relies on expectation, one
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must also be careful as to its possible harmful conse-
quences, which could be linked with the corollary, dis-
appointment. But here again this is an unsolved central
question in Evidence Based Medicine.
Conclusion
Implications for research
As in pre-scientific medicine, modern physicians need to
believe in the effectiveness of their techniques, and current
medical literature, with its strengths and also its limitations,
appears as the sophisticated way to generate such beliefs. It
also raises the ethical issue of the dissemination of scientific
evidence, for example, when editors permit reprints for the
pharmaceutical industry intended to present results to doc-
tors via a more commercial than epistemological approach,
as was the case for the Cipriani study [52].
Clinical implications
We did not find any superiority of one placebo over
the other. However, a critical approach to our results
prevents any firm conclusion on this apparently obvious
result. This result should remind clinicians to step
back to take a more objective view when interpreting
a scientific result, keeping in mind that Science can
never be actually sure that “sucrose = sucrose” in the
treatment of major depressive disorder. It is of crucial
importance for their practice, far more so than rank-
ing antidepressant efficacy.
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